athlete].'' Although biologic approaches are being used in all areas of orthopaedic surgery, sports medicine applications are the most common. The poor intrinsic healing potential of common soft tissue sports injuries, combined with the patient's desire to try anything to get back to activity, creates an environment where patients will try new and often unproven therapies. The doctor-patient relationship in sports medicine creates a permissive environment for use of these approaches-the patient requests these apparently cutting-edge approaches, and the doctor wants to be seen as offering the latest and greatest treatments. The result can be use of treatment options that are costly and unproven. This situation provides the sports medicine practitioner with the opportunity (and responsibility) to play a significant role in defining the appropriate, rational, and responsible use of these approaches.
To be clear, I am as bullish on biologic therapies as anyone. Biologic therapies such as stem cells, platelet-rich plasma (PRP), and cytokines have tremendous potential in orthopaedic sports medicine. 4, 5 Advances in several basic science areas, including cell biology, molecular biology, genomics, and biomaterials, are leading to improved understanding of biologic aspects of tissue degeneration, repair, and regeneration. Studies in developmental biology are uncovering the signaling molecules and specific cell lineages that are involved in tissue formation in the developing organism, and these findings may provide insight into new approaches for tissue healing and regeneration. Furthermore, studies in the field of mechanotransduction are elucidating how biomechanical stimuli affect the underlying biology of musculoskeletal tissues. These advances, coupled with new discoveries in biomaterials, make clear the tremendous potential of biologic approaches in sports medicine. Indeed, it is an exciting time in our field.
Despite promising basic science information and preclinical studies, there is currently a paucity of high-quality clinical data supporting use of these approaches in patients. Preclinical animal studies have provided some preliminary encouraging data. Animal studies have verified ''proof of principal'' for cell-based therapies, PRP, cytokines, and tissue-engineered implants. 2, 3, 6, 7 Although animal studies are critical to investigate the basic biology and evaluate the effect of new therapies for tissue healing, evaluation of biologics in healthy animals can show safety but are not a good way to demonstrate efficacy. Thus, there are distinct limitations to the ability to directly translate these findings to humans. Animal studies provide critical information that can inform the design of clinical trials in patients.
Optimal use of biologics will be aided by basic understanding of the desired mechanism of action. Take stem cells, for example. Implanted cells may work in several ways. The cells may directly participate in the repair response by integrating into the healing tissue, they may simply have a paracrine effect by stimulating and attracting intrinsic host cells, or they may function via their known immunomodulatory and anti-inflammatory properties. Better understanding of the fundamental mechanism(s) by which stem cells exert a positive effect will help guide their appropriate use. The variability between different cell sources and methods of preparation in stem cell applications and the resultant lack of precision in what is actually being delivered to the patient makes it all the more important that we understand the mechanism of action of implanted cells.
The diversity and variability in biologic activity of these agents is also magnified by the intrinsic variability in the tissue pathology being treated. We need to improve our understanding of the basic cellular and molecular mechanisms involved in degeneration and healing of orthopaedic soft tissues (meniscus, articular cartilage, tendon, ligament, and muscle). Advancement in technologies to study the genetic and epigenetic control of soft tissue homeostasis, injury, and repair will provide important insights to guide use of biologic therapies in our patients. Importantly, improved understanding of the genetic and epigenetic factors related to tissue injury and repair will also be helpful in predicting response to therapy. The area of genomics holds great potential to further our understanding of soft tissue injuries.
Rational and responsible use of biologics is dependent on identifying the biological targets and clinical targets. What are we trying to accomplish with use of biologics? Improved understanding of the underlying structural and compositional deficiencies of the injured tissue will help identify the biologic needs that we should target with these therapies. As we learn more about the underlying biology and pathophysiology of orthopaedic soft tissues, we will be better able to tailor the type of biologic therapy for the specific condition being treated. For example, if the primary pathology is poor vascularity, then biologic treatments that have an angiogenic effect may be most desirable. Conversely, if there is a paucity of available cells in the tissue, then simply adding the ''signals'' contained in PRP may not be enough; rather, an exogenous cell source may also be required. It is naive of us to think that the same type of PRP or stem cell preparation would work for a hamstring muscle strain, a torn meniscus, a degenerative rotator cuff tendon, or as an adjunct for articular cartilage repair. These are all very different tissues with different biologic requirements. One size does not and cannot fit all. Even within a specific tissue, there are likely very different biologic requirements for acute versus chronic injury. Understanding the basic biology of these processes will help to define what is needed to improve healing, and this can then guide the choice of optimal approach(es) for biologic augmentation.
We also need to identify the clinical needs that we want to address with biologic approaches. It makes sense that biologic therapies could be helpful in a patient who is biologically compromised (such as a diabetic or a smoker). But can biologics have a role in a younger, healthy patient? Can these agents lead to faster healing and earlier return to function, less postoperative pain, or better quality (and thus long-term function) of the healing tissue? As we learn more about the potentials and limitations of these therapies, we will be better able to tailor the use of biologics to specific clinical needs. This information will also help to define the metrics used to evaluate the outcome.
Although basic laboratory and translational research is critical to further our understanding of the biology of the conditions being treated as well as the mechanisms of action of various biologic treatment approaches, it is unrealistic to delay their use until such information is available. As it is clear that biologic augmentation approaches will continue to be used, I would encourage clinicians using these modalities to do so in controlled clinical trials. I would also encourage orthopaedic sports medicine clinicians to carry out translational studies in conjunction with basic scientists to allow rigorous evaluation of the biologic activity of these agents and to relate that to relevant measures of clinical outcome. Orthopaedic clinicians can work with basic scientists to design the most effective preclinical (animal) and clinical studies. This type of partnership is the optimal way to evaluate new therapies and move the field forward in a meaningful way. The clinician knows the clinical problems and the current limitations in our treatments, and is thus in the best position to help set the research agenda. The involvement of clinicians in basic and translational studies is also critical, since it is the clinician who understands what can realistically be used in patients. These types of translational studies are needed to further our understanding and to inform the use of biologic therapies in orthopaedic sports medicine. Such carefully designed clinical translational studies can be done in parallel with basic laboratory studies.
In consideration of rigorous clinical studies to evaluate biologic therapies, we need to identify biomarkers to characterize the biologic activity of the material delivered to a patient. This might involve measurement of a specific sentinel cytokine(s), characterization of the specific phenotype of stem cells delivered to a patient, assessment of biological activity in an in vitro assay, measurements of platelet activation status, or some other metric. Progress in this field will come from identification of assays or biomarkers that reflect the biologic activity of the substance implanted. This information can then be correlated with clinical and imaging outcomes. This is the only way to deepen our understanding of the effect of biologic therapies on both patient-centered measures of symptoms and the actual structural response of the treated tissue. The critical limitation in the literature right now is that we often do not really know the biologic activity of the substance delivered to the patient in most clinical studies. Although general characteristics are often reported, such as platelet or white cell count in PRP or cell number in stem cell approaches, we do not know how or if these simple measures relate to biologic activity of the material. Because of the tremendous variability among various preparations, it is incumbent upon us to develop these measures of biologic activity that can be correlated with clinical outcomes.
In addition to reporting some measure of biologic activity of the implanted material, standardized reporting of relevant patient-related factors also needs to be considered. A number of factors may affect the patient response to biologic agents, including sex, age, concomitant medications, underlying medical conditions, and smoking status. Similarly, the mechanical loads on the healing tissue will clearly play a critical role, and thus the posttreatment rehabilitation protocol and patient activity levels need to be recorded. Further work is required to establish consensus on the relevant patient-related factors that should be measured and reported.
There is no doubt that biologic therapies have great promise and potential to augment biologic activity of difficult-to-heal musculoskeletal tissues. However, I believe that sports medicine practitioners need to avoid the indiscriminate use of these approaches until we have better data to identify the appropriate clinical conditions to be treated and the optimal types and preparations of biologic therapies. A common argument for liberal use of biologic approaches using autologous material is that they are safe and thus there is the sense that ''it might help and won't hurt.'' This approach can sometimes be shortsighted, as unexpected and unintended adverse effects may lead to a premature conclusion of lack of efficacy and dampening enthusiasm among important stakeholders, including third-party payers, regulatory bodies, clinicians, and our patients. This situation can lead to premature abandonment of an otherwise promising therapy. A too-early and indiscriminate use of therapies that are poorly understood with resultant equivocal or even adverse outcomes can lead to a situation where we ''throw out the baby with the bathwater.'' It is for these reasons that I advocate a measured and careful approach to the use of biologic therapies in orthopaedic sports medicine.
A good example of what can occur when a poorly understood therapy is used is the example of PRP treatment for rotator cuff tendon repair. This has been one of the more frequently studied areas related to PRP, with some studies showing positive results, most studies demonstrating no effect, and a small number even suggesting a possible negative effect on structural tendon healing. 1, 5, 8, 9 Given the inherent degenerative changes in rotator cuff tendinopathy, it seems likely that biologic augmentation techniques could be helpful here, and in fact I believe that a more refined and optimized approach using PRP or a related blood product may well have a positive effect in rotator cuff tendon repair. We are just not there yet-we need more research to understand the best way to use this potentially effective modality. For the PRP example here, we need to determine the optimal PRP formulation (leukocyte and platelet number, other plasma proteins), platelet activation status (when and how to initiate degranulation), need for a carrier vehicle (fibrin matrix or collagen-based scaffold), and dosing regimen (single versus serial injection, intraoperative versus delayed injection). Wellintentioned but premature use may lead to premature abandonment of a potentially effective therapy.
The rotator cuff example also points out the importance of choosing the appropriate outcome metric. What are we trying to achieve with use of biologics? Maybe ''healed'' versus ''not healed'' is not the optimal outcome. Perhaps we should consider other metrics, such as ultimate tissue quality at the healed site, time to achieve tissue healing, or some other clinical measure such as restoration of motion or strength, or postoperative pain levels. Defining and measuring the appropriate outcome measure is critical to furthering our understanding of the optimal use of biologic therapies.
In summary, biologic approaches clearly have tremendous potential in sports medicine. There is an accumulating wealth of basic science data demonstrating and supporting the concept of biologic augmentation. The combination of patients with high expectations to remain active, soft tissue injuries with poor intrinsic healing potential, and frequent media exposure of prominent athletes being treated at ''regenerative medicine centers'' creates an environment where our patients continue to ask about and seek these novel approaches for treating their difficult-to-heal injuries. This places the sports medicine practitioner in an important position where we have the opportunity and responsibility to play a significant role in defining the appropriate, rational, and responsible use of these approaches. It is incumbent on us to understand these perils attendant to the premature or indiscriminate use of biologics so that we can define the path forward to realize the exciting potential of these therapies. Scott A. Rodeo, MD New York, New York
